By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Sagimet Biosciences Inc (SGMT) stock saw a modest uptick, ending the day at $4.62 which represents a slight increase of $0.42 or 10.00% from the prior close of $4.2. The stock opened at $4.29 and ...

Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.16 which represents a slight increase of $0.08 or 3.85% from the prior close of $2.08. The stock opened at $2.05 and ...

NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...

Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...

January 14, 2025--(BUSINESS WIRE)--Valent BioSciences in partnership with Meister ... by someone else at BiostimulantInnovator.com through March 12, 2025. "Valent BioSciences is looking forward ...

NEW ORLEANS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they ...

Anthem Biosciences on Tuesday (December 31 ... Its profit after tax for the year ended March 31, 2024, was ₹367 crore. Sai Life Sciences Ltd, Syngene International, Suven Life Sciences and ...